CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference
CalciMedica (Nasdaq: CALC), a clinical-stage biopharmaceutical company specializing in CRAC channel inhibition therapies for inflammatory and immunologic conditions, has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference.
The company's CEO, Rachel Leheny, Ph.D., will deliver a presentation on Wednesday, April 9, 2025, at 11:00 a.m. PT. Interested parties can access the live webcast through CalciMedica's IR website in the 'Upcoming Events' section. The presentation recording will remain available on the company's website for a 90-day period.
CalciMedica (Nasdaq: CALC), un'azienda biofarmaceutica in fase clinica specializzata in terapie per l'inibizione dei canali CRAC per condizioni infiammatorie e immunologiche, ha annunciato la sua partecipazione alla prossima Jones Healthcare and Technology Innovation Conference.
Il CEO dell'azienda, Rachel Leheny, Ph.D., terrà una presentazione mercoledì 9 aprile 2025, alle 11:00 PT. Le parti interessate possono accedere alla diretta web tramite il sito IR di CalciMedica nella sezione 'Eventi Futuri'. La registrazione della presentazione sarà disponibile sul sito dell'azienda per un periodo di 90 giorni.
CalciMedica (Nasdaq: CALC), una empresa biofarmacéutica en etapa clínica especializada en terapias de inhibición de canales CRAC para condiciones inflamatorias e inmunológicas, ha anunciado su participación en la próxima Jones Healthcare and Technology Innovation Conference.
La CEO de la empresa, Rachel Leheny, Ph.D., realizará una presentación el miércoles 9 de abril de 2025, a las 11:00 a.m. PT. Las partes interesadas pueden acceder a la transmisión en vivo a través del sitio web de IR de CalciMedica en la sección 'Eventos Futuros'. La grabación de la presentación estará disponible en el sitio web de la empresa durante un período de 90 días.
CalciMedica (Nasdaq: CALC)는 염증 및 면역 질환을 위한 CRAC 채널 억제 요법을 전문으로 하는 임상 단계의 생명공학 회사로, 다가오는 Jones Healthcare and Technology Innovation Conference에 참여할 것이라고 발표했습니다.
회사의 CEO인 Rachel Leheny 박사는 2025년 4월 9일 수요일 오전 11시 PT에 발표를 진행할 예정입니다. 관심 있는 분들은 CalciMedica의 IR 웹사이트 'Upcoming Events' 섹션을 통해 실시간 웹캐스트에 접근할 수 있습니다. 발표 녹화는 회사 웹사이트에서 90일 동안 이용 가능합니다.
CalciMedica (Nasdaq: CALC), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies d'inhibition des canaux CRAC pour les conditions inflammatoires et immunologiques, a annoncé sa participation à la prochaine Jones Healthcare and Technology Innovation Conference.
La PDG de l'entreprise, Rachel Leheny, Ph.D., fera une présentation le mercredi 9 avril 2025 à 11h00 PT. Les parties intéressées peuvent accéder au webinaire en direct via le site IR de CalciMedica dans la section 'Événements à venir'. L'enregistrement de la présentation restera disponible sur le site de l'entreprise pendant une période de 90 jours.
CalciMedica (Nasdaq: CALC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf CRAC-Kanal-Inhibitions-Therapien für entzündliche und immunologische Erkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jones Healthcare and Technology Innovation Conference angekündigt.
Die CEO des Unternehmens, Rachel Leheny, Ph.D., wird am Mittwoch, den 9. April 2025, um 11:00 Uhr PT eine Präsentation halten. Interessierte Parteien können über die IR-Website von CalciMedica im Abschnitt 'Bevorstehende Veranstaltungen' auf das Live-Webcast zugreifen. Die Aufzeichnung der Präsentation wird für einen Zeitraum von 90 Tagen auf der Website des Unternehmens verfügbar sein.
- None.
- None.
A live webcast of the presentation can be accessed in the "Upcoming Events" section of CalciMedica's IR website at https://ir.calcimedica.com/. A replay of the webcast will be archived on the Company's website for 90 days.
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS). The Company has also completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF) with data expected around the end of 2025 and continuing to support the ongoing investigator-initiated Phase 1/2 trial (called CRSPA – NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT) with an update expected in the second half of 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in
Contact Information
Argot Partners
Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-participate-in-the-jones-healthcare-and-technology-innovation-conference-302416105.html
SOURCE CalciMedica, Inc.
FAQ
When is CalciMedica (CALC) presenting at the Jones Healthcare Conference 2025?
How long will CalciMedica's (CALC) Jones Conference presentation be available for replay?
Where can investors watch CalciMedica's (CALC) Jones Conference presentation?
What type of therapies is CalciMedica (CALC) developing?
